- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02527057
Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophageal Cancer
Diffusion-weighted Magnetic Resonance Imaging(DW-MRI) for Early Response Assessment of Neoadjuvant Chemoradiation Therapy(Neo-CRT) in Patients With Esophageal Squamous Cell Carcinoma(ESCC)
Esophageal carcinoma is a lethal disease, causing more than 400,000 deaths annually worldwide. Primary surgery results in microscopically positive resection margins (R1) in 25% patients, and the 5-year overall survival(OS) for such patients rarely exceeds 40%. Concurrent chemoradiation followed by surgery results in better survival than single-modality treatments, and thus National Comprehensive Cancer Network(NCCN) recommends concurrent chemoradiation as preoperative or definitive treatment for patients with stage II or III esophageal cancer. However, neoadjuvant chemoradiation may not be effective in some subgroup of these patients, and its toxicity can increase perioperative mortality and delay or preclude surgery. The ability to distinguish tumors that will respond or not respond to such therapy remains an urgent priority. Diffusion-weighted magnetic resonance imaging(DW-MRI) is based on the extent of mobility of water protons, as quantified by the apparent diffusion coefficient (ADC). The ADC is a measure of the extent of free diffusion of water molecules within tissues, which is mainly influenced by cell organization, size, and density. Cell death leads to a loss of cell membrane integrity and density and leads to increases in ADC values. The ADC has emerged as a potential biomarker of response to cancer therapy. However, no one has published findings regarding the potential correlation between changes in ADC and response of esophageal cancer to chemoradiation. Clarifying the potential predictive value of DW-MRI for predicting response to such therapy is important for the delivery of appropriately tailored treatment.
Investigators hypothesized that DW-MRI can predict the success (or failure) of neoadjuvant chemoradiation in esophageal squamous cell carcinoma(ESCC), hence identify patients at high risk of treatment failure from such therapy. Investigators will test this hypothesis with two specific aims: (1) assess the ability of ADC to predict pathologic response to treatment; and (2) assess the ability of ADC to predict disease-free survival and overall survival.
Aperçu de l'étude
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Lieux d'étude
-
-
Hunan
-
Changsha, Hunan, Chine
- Recrutement
- Hunan province tumor pospital
-
Contact:
- shengqi wu, M.D.
- Numéro de téléphone: 13807316075
- E-mail: wushengqi@hnszlyy.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- T1bN+ M0(T1b means that tumor invades submucosa) or T2-T4aN0/+ M0 (T4a means resectable tumor invading pleura, pericardium, or diaphragm) according to American Joint Committee on Cancer (AJCC)Cancer Stage 7th
- Pathological identified esophageal squamous cell cancer
- Karnofsky Performance Status(KPS)≥70
- Tolerable and agree for Intensity-Modulated Radiation Therapy(IMRT) and concurrent chemoradiotherapy
- Without severe other diseases
- Informed consent
Exclusion Criteria:
- Cervical esophagus cancer;
- Had received prior chemotherapy and thoracic radiotherapy
- Distant metastasis before treatment, including: pleural, pericardial or peritoneal cytology ,involvement of distant organs including the lungs, liver, bone, brain or non-regional lymph nodes
- Pregnant and lactating women
- Serious complications
- Other primary malignancies
- Cannot perform DW-MRI at specified time
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Pathologic response
Délai: after surgury
|
Pathologic response will be assessed after surgery by two pathologists blinded to clinical and radiologic findings in the surgical specimen as follows : P0: no residual cancer cells P1: 1%-50% residual cancer cells; rare individual cancer cells or minute clusters of cancer cells P2: More than 50% residual cancer cells, often grossly identifiable at primary site
|
after surgury
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Overall survival
Délai: up to 60 months
|
Overall survival is defined as the time (in months) from the date of admission to the date of death from any cause or last follow-up
|
up to 60 months
|
Progression free survival
Délai: up to 60 months
|
Overall survival is defined as the time (in months) from the date of admission to the date of progression
|
up to 60 months
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 89000--0000
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Carcinome de l'œsophage
-
Novartis PharmaceuticalsRecrutementAdvanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,MélanomePays-Bas, Corée, République de, Espagne, Taïwan, Japon, Italie, États-Unis, Singapour, Canada
Essais cliniques sur DW-MRI
-
Universitaire Ziekenhuizen KU LeuvenInconnueRécurrence | Cancer du col de l'utérus | IRM pondérée en diffusionBelgique
-
Uludag UniversityInconnueCancer du col de l'utérus | Cancer de l'endomètreTurquie
-
Mahidol UniversityComplétéFibrose, FoieThaïlande
-
University Health Network, TorontoPeter Munk Cardiac CentreRecrutementForamen ovale perméableCanada
-
General University Hospital, PragueCharles University, Czech RepublicRecrutementCancer du col de l'utérus | Métastase ganglionnaireTchéquie
-
Daewon Pharmaceutical Co., Ltd.Inconnue
-
Miulli General HospitalInconnueUrémie | Complication de l'hémodialyseItalie
-
Air Force Military Medical University, ChinaInconnueTumeurs pulmonairesChine
-
Abbott Medical DevicesRésilié
-
Centre Hospitalier St AnneAssistance Publique - Hôpitaux de Paris; National Research Agency, France; CENIR... et autres collaborateursInconnueDépression chez les adolescentsFrance